XBB. 1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN. 1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike
protein of the SARS-CoV-2 XBB. 1.5 subvariant, but their immunogenicity in humans has yet …
protein of the SARS-CoV-2 XBB. 1.5 subvariant, but their immunogenicity in humans has yet …
XBB. 1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.
1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and …
1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and …
Effectiveness of Omicron XBB. 1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN. 1 variants, prospective cohort study, the Netherlands, October …
AJ Huiberts, CE Hoeve, B de Gier, J Cremer… - …, 2024 - eurosurveillance.org
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB. 1.5 vaccination
against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB …
against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB …
Safety and immunogenicity of the monovalent omicron XBB. 1.5-adapted BNT162b2 COVID-19 vaccine in individuals≥ 12 years old: a phase 2/3 trial
J Gayed, O Diya, FS Lowry, X Xu, V Bangad, F Mensa… - Vaccines, 2024 - mdpi.com
Vaccination remains an important mitigation tool against COVID-19. We report 1-month
safety and preliminary immunogenicity data from a substudy of an ongoing, open-label …
safety and preliminary immunogenicity data from a substudy of an ongoing, open-label …
Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines
G Kassianos, P MacDonald, I Aloysius, S Pather - Vaccines, 2024 - mdpi.com
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the
waning of immunity over time has necessitated the use of booster doses of original …
waning of immunity over time has necessitated the use of booster doses of original …
[HTML][HTML] Antigenic cartography using hamster sera identifies SARS-CoV-2 JN. 1 evasion seen in human XBB. 1.5 booster sera
W Wang, GL Bhushan, S Paz, CB Stauft, P Selvaraj… - bioRxiv, 2024 - ncbi.nlm.nih.gov
Antigenic assessments of SARS-CoV-2 variants inform decisions to update COVID-19
vaccines. Primary infection sera are often used for assessments, but such sera are rare due …
vaccines. Primary infection sera are often used for assessments, but such sera are rare due …
Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission
M Benlarbi, S Ding, E Belanger, A Tauzin, R Poujol… - bioRxiv, 2024 - biorxiv.org
The continued evolution of SARS-CoV-2 requires persistent monitoring of its subvariants.
Omicron subvariants are responsible for the vast majority of SARS-CoV-2 infections …
Omicron subvariants are responsible for the vast majority of SARS-CoV-2 infections …